Symic Bio Announces Last Patient Enrolled in Osteoarthritis Phase 2b Study MODIFY3

DENMARK & SAN FRANCISCO, October 8, 2020 – Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that the last patient had been enrolled in its Phase 2b OA (osteoarthritis) study. The study, dubbed MODIFY3, is a double-blinded, randomized controlled trial investigating Symic Bio's DMOAD (disease-modifying OA drug) candidate, SB-061 vs. placebo control.

A total of 288 patients were enrolled throughout multiple sites in Europe, led by the CRO Sanos Clinics. "We are incredibly pleased at the quality of work by Sanos Clinics, and the speed in which the trial was fully enrolled," said Ken Horne, who is responsible SB-061 business development and partnering. "Despite interruptions due to the on-going COVID pandemic, Sanos was able to complete enrollment ahead of schedule." Top-line data from MODIFY3 is anticipated in the first quarter of 2022.

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting peripheral vascular disease. For additional information please visit the company's website at www.symic.bio

Investor Contact
ir@symic.bio

Media Contacts
pr@symic.bio